key: cord-0684564-x46cf7rg
authors: Salvagno, Gian Luca; Henry, Brandon M.; Lippi, Giuseppe
title: Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine
date: 2021-08-17
journal: J Occup Environ Med
DOI: 10.1097/jom.0000000000002362
sha: 9c87268b0416e1f89fd9399b7252ab60c1831c39
doc_id: 684564
cord_uid: x46cf7rg

nan

W e read with interest the article by Iddins et al., 1 reporting the immune response anti-SARS-CoV-2 IgG against the receptor binding domain (RBD) spike protein in healthcare workers. Since the risk of infection and poor outcomes seem also largely dependent on efficient anti-SARS-CoV-2 IgA response, assessing this antibody class is pivotal. 2 Thus, we analyzed serum levels of total anti-spike RBD Ig, (Elecsys Anti-SARS-CoV-2S immunoassay on Roche Cobas 6000; Roche Diagnostics, Basel, Switzerland), anti-spike RBD IgG (ACCESS SARS-CoV-2 IgG II on Access 2; Beckman Coulter, Brea CA), and anti-spike S1 subunit IgA (Anti-SARS-CoV-2 ELISA IgA, manual ELISA; Euroimmun, Lübeck, Germany), in 24 healthcare workers undergoing vaccination with BNT162b2 mRNA COVID-19 at Peschiera del Garda hospital (Italy). This cohort comprised two matched samples of 12 baseline SARS-CoV-2 seronegative subjects (median age 40 years, interquartile range 31-52 years; 6 women) and 12 baseline SARS-CoV-2 seropositive subjects (median age 41 years, interquartile range 31-52 years; 6 women). Serum samples were drawn before the first vaccine dose, at 21 days (before the second vaccine dose) and 50 days afterwards. The study was conducted in accordance with the Helsinki Declaration and cleared by the Ethics Committee of Verona and Rovigo Provinces (3246CESC).

The results are summarized in Table 1 . Levels of all antibodies increased in both baseline SASR-CoV-2 seronegative and seropositive cohorts, though such increase continued after the second dose in baseline seronegative subjects, while reached a plateau in baseline seropositive subjects. In agreement with earlier data published by Vicenti et al, 3 anti-SARS-CoV-2 RBD IgG levels after the first dose in baseline seropositive subjects were comparable to those achieved after two doses in baseline seronegative subjects (340.4 vs. 341.2 AU/mL; P ¼ 0.259), while those of anti-SARS-CoV-2 RBD Total Ig (20,585.5 vs. 1629.0 AU/mL; P < 0.001) and anti-SARS-CoV-2 S1 Ig A (8.97 vs. 5.76 ratio; P < 0.001) were significantly higher. After the second dose, levels of anti-SARS-CoV-2 RBD Total Ig and Anti-SARS-CoV-2 S1 Ig A were still significantly higher in baseline seropositive subjects than in the seronegative cohort (both P < 0.001), while anti-SARS-CoV-2 RBD IgG levels were comparable (P ¼ 0.068).

Our results, reporting anti-SARS-CoV-2 IgA antibodies response after BNT162b2 mRNA COVID-19 vaccination, suggest that consideration could be given to delay and/or omit the second vaccine dose in baseline SARS-CoV-2 seropositive subjects. 

mRNA SARS-CoV-2 immunization confers robust antibody response in occupational healthcare workers and fosters workplace safety

IgA antibodies and IgA deficiency in SARS-CoV-2 infection

Singledose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection